Impaired fibrinolytic capacity and tissue plasminogen activator release in patients with restenosis after percutaneous transluminal coronary angioplasty (PTCA). 1989

W Kirschstein, and S Simianer, and C E Dempfle, and H Keller, and B Stegaru, and P Rentrop, and D L Heene
I. Medizinische Klinik, Klinikum Mannheim, FRG.

To assess the role of the fibrinolytic system in the pathogenesis of restenosis after percutaneous transluminal coronary angioplasty (PTCA), we determined the components of this system in a retrospective study, including 16 patients with restenosis (gr. A) and 19 patients with long-term success (gr. B). In both groups at baseline fibrinolytic activity (FA) is unchanged, whereas tissue plasminogen activator antigen (tPA-Ag) is significantly increased (gr. A: 147.0%; gr. B: 139.8%; p less than 0.01). Fibrinolytic capacity (FC) and tPA-Ag release are significantly reduced in the restenosis group (FC: 46.5%, p less than 0.05; tPA-Ag release: 48.3%, p less than 0.01) compared to normal controls as well as to gr. B (FC: 84.3%, p less than 0.05; tPA-Ag release: 79.0%, p less than 0.05). Relating to the contact activation system, F XII (79.5%, p less than 0.05) is significantly, and F XI (82.3%) is clearly reduced in gr. A. Protein C (PC) is significantly elevated in gr. B (117.5%, p less than 0.05). There is a negative correlation between plasminogen activator inhibitor (PAI 1) and HDL-cholesterol (r = 0.37, p less than 0.05). It appears, that there is a typical pattern of defective fibrinolysis in patients with restenosis after PTCA and that this might be a pathogenetic factor in the development of restenosis.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D005260 Female Females
D005342 Fibrinolysis The natural enzymatic dissolution of FIBRIN. Fibrinolyses
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective

Related Publications

W Kirschstein, and S Simianer, and C E Dempfle, and H Keller, and B Stegaru, and P Rentrop, and D L Heene
October 2004, Revue medicale de Liege,
W Kirschstein, and S Simianer, and C E Dempfle, and H Keller, and B Stegaru, and P Rentrop, and D L Heene
January 1992, Annals of the Academy of Medicine, Singapore,
W Kirschstein, and S Simianer, and C E Dempfle, and H Keller, and B Stegaru, and P Rentrop, and D L Heene
March 1992, Acta radiologica (Stockholm, Sweden : 1987),
W Kirschstein, and S Simianer, and C E Dempfle, and H Keller, and B Stegaru, and P Rentrop, and D L Heene
February 1992, Herz,
W Kirschstein, and S Simianer, and C E Dempfle, and H Keller, and B Stegaru, and P Rentrop, and D L Heene
December 1989, Kokyu to junkan. Respiration & circulation,
W Kirschstein, and S Simianer, and C E Dempfle, and H Keller, and B Stegaru, and P Rentrop, and D L Heene
April 1990, Casopis lekaru ceskych,
W Kirschstein, and S Simianer, and C E Dempfle, and H Keller, and B Stegaru, and P Rentrop, and D L Heene
May 1988, The American journal of cardiology,
W Kirschstein, and S Simianer, and C E Dempfle, and H Keller, and B Stegaru, and P Rentrop, and D L Heene
January 1984, Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi,
W Kirschstein, and S Simianer, and C E Dempfle, and H Keller, and B Stegaru, and P Rentrop, and D L Heene
January 1985, Zeitschrift fur Kardiologie,
W Kirschstein, and S Simianer, and C E Dempfle, and H Keller, and B Stegaru, and P Rentrop, and D L Heene
January 1986, Rinsho hoshasen. Clinical radiography,
Copied contents to your clipboard!